Avelumab in unresectable/metastatic, progressive, grade 2–3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials

D.L. Chan; V. Rodriguez-Freixinos; M. Doherty; K. Wasson; N. Iscoe; W. Raskin; J. Hallet; S. Myrehaug; C. Law; A. Thawer; K. Nguyen; S. Singh

doi:10.1016/j.ejca.2022.03.029

journal article Jul 01, 2022

Avelumab in unresectable/metastatic, progressive, grade 2–3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials

D.L. Chan V. Rodriguez-Freixinos M. Doherty K. Wasson N. Iscoe W. Raskin J. Hallet S. Myrehaug C. Law A. Thawer K. Nguyen S. Singh

European Journal of Cancer Vol. 169 pp. 74-81 · Elsevier BV

View at Publisher Save 10.1016/j.ejca.2022.03.029

Topics

No keywords indexed for this article. Browse by subject →

References

36

[1]

Hallet "Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes" Cancer (2015) 10.1002/cncr.29099

[2]

Hadoux "Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma" Endocr Relat Cancer (2015) 10.1530/erc-15-0075

[3]

Hentic "FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3" Endocr Relat Cancer (2012) 10.1530/erc-12-0002

[4]

Thomas "Outcomes of capecitabine and temozolomide (CAPTEM) in advanced neuroendocrine neoplasms (NENs)" Cancers (2020) 10.3390/cancers12010206

[5]

Thang "Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis" Eur J Nucl Med Mol Imag (2018) 10.1007/s00259-017-3821-2

[6]

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez et al.

New England Journal of Medicine 2019 10.1056/nejmoa1910836

[7]

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Joaquim Bellmunt, Ronald de Wit, David J. Vaughn et al.

New England Journal of Medicine 2017 10.1056/nejmoa1613683

[8]

Mok "Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial" Lancet (2019) 10.1016/s0140-6736(18)32409-7

[9]

Strosberg "Efficacy and safety of pembrolizumab in previously treated advanced neuroendocrine tumors: results from the phase II KEYNOTE-158 study" Clin Cancer Res (2020) 10.1158/1078-0432.ccr-19-3014

[10]

Vijayvergia "Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials" Br J Cancer (2020) 10.1038/s41416-020-0775-0

[11]

Yao "Spartalizumab in metastatic, well/poorly-differentiated neuroendocrine neoplasms" Endocr Relat Cancer (2021) 10.1530/erc-20-0382

[12]

Weber "Immune checkpoint inhibitors in the treatment of patients with neuroendocrine neoplasia" Oncol Res Treat (2018) 10.1159/000488996

[13]

Kaufman (2016)

[14]

Nghiem "PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma" N Engl J Med (2016) 10.1056/nejmoa1603702

[15]

Lokuhetty (2019)

[16]

(2017)

[17]

The 2015 World Health Organization Classification of Lung Tumors

William D. Travis, Elisabeth Brambilla, Andrew G. Nicholson et al.

Journal of Thoracic Oncology 2015 10.1097/jto.0000000000000630

[18]

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E.A. Eisenhauer, P. Therasse, J. Bogaerts et al.

European Journal of Cancer 2009 10.1016/j.ejca.2008.10.026

[19]

Basturk "The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms" Am J Surg Pathol (2015) 10.1097/pas.0000000000000408

[20]

Rindi "The 2010 WHO classification of digestive neuroendocrine neoplasms: a critical appraisal four years after its introduction" Endocr Pathol (2014) 10.1007/s12022-014-9313-z

[21]

Fottner

[22]

Mehnert "Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: results from the KEYNOTE-028 study" Cancer (2020) 10.1002/cncr.32883

[23]

Yao Ann Oncol (2018)

[24]

Lu "Efficacy, safety and biomarkers of toripalimab in patients with recurrent or metastatic neuroendocrine neoplasms: a multiple-center phase Ib trial" Clin Cancer Res (2020) 10.1158/1078-0432.ccr-19-4000

[25]

Capdevila "1157O A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: the DUNE trial (GETNE 1601)" Ann Oncol (2020) 10.1016/j.annonc.2020.08.1370

[26]

Patel "A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART SWOG 1609) in patients with nonpancreatic neuroendocrine tumors" Clin Cancer Res (2020) 10.1158/1078-0432.ccr-19-3356

[27]

Puccini "Comprehensive genomic profiling of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs)" Clin Cancer Res (2020) 10.1158/1078-0432.ccr-20-1804

[28]

Marabelle "Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study" Lancet Oncol (2020) 10.1016/s1470-2045(20)30445-9

[29]

Xing "Immune checkpoint markers in neuroendocrine carcinoma of the digestive system" Front Oncol (2020) 10.3389/fonc.2020.00132

[30]

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

Zachary R. Chalmers, Caitlin F. Connelly, David Fabrizio et al.

Genome Medicine 2017 10.1186/s13073-017-0424-2

[31]

Luo "The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response" Oncotarget (2016) 10.18632/oncotarget.7631

[32]

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Brian I. Rini, Elizabeth R. Plimack, Viktor Stus et al.

New England Journal of Medicine 2019 10.1056/nejmoa1816714

[33]

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

Leora Horn, Aaron S. Mansfield, Aleksandra Szczęsna et al.

New England Journal of Medicine 2018 10.1056/nejmoa1809064

[34]

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz-Ares, Mikhail Dvorkin, Yuanbin Chen et al.

The Lancet 2019 10.1016/s0140-6736(19)32222-6

[35]

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Scott J. Antonia, Augusto Villegas, Davey Daniel et al.

New England Journal of Medicine 2018 10.1056/nejmoa1809697

[36]

Chung "Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study" J Clin Oncol (2019) 10.1200/jco.18.01265

Metrics

32

Citations

36

References

Details

Published: Jul 01, 2022
Vol/Issue: 169
Pages: 74-81
License: View

Authors

D

D.L. Chan

V

V. Rodriguez-Freixinos

Brigham and Women's Hospital

Cite This Article

D.L. Chan, V. Rodriguez-Freixinos, M. Doherty, et al. (2022). Avelumab in unresectable/metastatic, progressive, grade 2–3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials. European Journal of Cancer, 169, 74-81. https://doi.org/10.1016/j.ejca.2022.03.029

Avelumab in unresectable/metastatic, progressive, grade 2–3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials

You May Also Like